F10 and cancer: Non‐vitamin K antagonist oral anticoagulants (NOACs), including direct thrombin inhibitor dabigatran and factor Xa inhibitors, are increasingly used in patients with VTE or AF because of their favorable efficacy and safety, replacing traditional vitamin K antagonist (VKA) in the general population wherein there are a small proportion of cancer patients.5, 6, 7, 8, 9, 10, 11, 12